Business Context and Reporting Period
Company: Arrowhead Research Corporation (Arrowhead)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Arrowhead is a development-stage nanotechnology company operating a portfolio of subsidiaries focused on life sciences, electronics, and energy. Key subsidiaries include Calando Pharmaceuticals (RNAi therapeutics), Unidym (carbon nanotubes), and Tego BioSciences (fullerene-based pharmaceuticals). The company also holds minority interests in private companies and sponsors university research.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 |
Nine Months Ended June 30, 2008 |
Nine Months Ended June 30, 2007 |
|---|---|---|---|
| Revenue | $235,372 | $1,362,999 | $629,994 |
| Cost of Goods Sold | $160,742 | $882,766 | $347,601 |
| Gross Profit | $74,630 | $480,233 | $282,393 |
| Operating Expenses | $9,971,212 | $23,923,823 | $29,122,096 |
| Operating Loss | $(9,896,582) | $(23,443,590) | $(28,839,703) |
| Net Loss | $(7,502,162) | $(18,430,751) | $(22,358,528) |
| Cash and Equivalents (End of Period) | $13,823,480 (as of June 30, 2008) | ||
| Net Cash Used in Operating Activities | $(19,200,980) (Nine Months 2008) |
Liquidity: As of June 30, 2008, the company held $13.8 million in cash and cash equivalents. Total current assets were $14.5 million against current liabilities of $2.6 million. The company has no long-term debt.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss for the nine months ended June 30, 2008, decreased to $18.4 million from $22.4 million in the prior year. This improvement is primarily attributed to a $9.6 million non-cash charge for purchased in-process research and development (IPR&D) recorded in the prior year related to the acquisition of Carbon Nanotechnologies, Inc. (CNI).
- Revenue Growth: Revenue for the nine months ended June 30, 2008, increased to $1.36 million from $0.63 million in the prior year. Growth was driven by increased grant funding ($748,000 vs. $409,000) and sales of carbon nanotubes ($507,000 vs. $207,000) from the Unidym subsidiary.
- Operating Expenses: Excluding the one-time IPR&D charge in the prior year, operating expenses increased due to expanded headcount at Unidym and Calando, higher stock-based compensation ($2.57 million vs. $1.49 million), and increased patent and professional service fees.
- Discontinued Operations: Aonex Technologies, Inc. was sold in May 2008. Results are now reported as discontinued operations, resulting in a net gain of $285,174 for the quarter and a loss of $153,605 for the nine-month period.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Cash Runway: Management believes current cash reserves are sufficient to fund operations through the fourth quarter of fiscal 2008. Additional capital will be required thereafter.
- Financing: The company has an effective Form S-3 registration statement allowing for the issuance of up to $50 million in securities. Unidym recently raised $4 million in a private placement.
- Subsidiary Progress: Calando commenced Phase I clinical trials for CALAA-01 in May 2008 and plans to begin Phase II trials for IT-101 later in the year. Unidym continues to scale manufacturing of carbon nanotubes and transparent conductive films.
Risks and Contingencies:
- Capital Needs: The company is a development-stage entity with no history of profitability. Failure to raise additional capital could force a reduction in operations or abandonment of research programs.
- Regulatory & Clinical Risk: Success depends on FDA approvals for Calando's drug candidates. Delays in clinical trials or manufacturing could significantly increase costs.
- Intellectual Property: The company faces risks regarding the enforcement of its patents and potential infringement claims from third parties in the rapidly evolving nanotechnology sector.
- Facility Leases: Unidym's Houston facility lease expired, and the company is operating on a month-to-month basis while seeking new locations, creating potential relocation costs and operational disruption.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the $13.8 million cash balance against the projected burn rate for the remainder of fiscal 2008 and the timeline for the next capital raise.
- Revenue Quality: Assess the sustainability of revenue, noting that a significant portion ($748,000 of $1.36M for the nine months) is derived from grants rather than commercial product sales.
- Subsidiary Valuation: Review the ownership percentages and capital commitments for subsidiaries (Calando, Unidym, Tego) and minority investments (Nanotope, Leonardo Biosystems) to understand dilution risks.
- Clinical Milestones: Monitor the progress and safety data of Calando's Phase I trial for CALAA-01 and the upcoming Phase II trial for IT-101.
- Discontinued Operations Earn-out: Track the potential earn-out payments from the sale of Aonex Technologies, which could total up to $7.95 million based on future performance milestones.